Back to search
FDAFDA · Food and drugs·Recall number D-0107-2027

Lidocaine Ointment USP, 5.0 % 50g JAR, Rx only, Packaged and Distributed by: Direct Rx Dawsonville, GA 30534, NDC 72189-0211-50

Published November 4, 2026 · Recall initiated: September 29, 2026

Summary

FDA records drug Class II recall D-0107-2027, published November 4, 2026 and initiated September 29, 2026. Recalling firm: Direct Rx; Status: Ongoing; Reported quantity: 493 jars; Lot: LOT#: 03AP2511, 30AP2518, 18JU2519, 18JU2520, Exp. Date 04/30/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Direct Rx
Distributor
Nationwide within the United States
Lot
LOT#: 03AP2511, 30AP2518, 18JU2519, 18JU2520, Exp. Date 04/30/2027.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lidocaine Ointment USP, 5.0 % 50g JAR, Rx only, Packaged and Distributed by: Direct Rx Dawsonville, GA 30534, NDC 72189-0211-50 recalled?

Yes. FDA published recall D-0107-2027 on November 4, 2026. Reported hazard: Subpotent Drug

What should I do if I have this product?

Voluntary: Firm initiated · Letter